BioLASCO Taiwan Co. Ltd.

As of June 30, 2026, BioLASCO Taiwan Co. Ltd. carries a market capitalization of 765.80M, placing it among publicly traded companies globally. Its enterprise value stands at 711.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, BioLASCO Taiwan Co. Ltd. has 25.61M shares outstanding.

As of June 30, 2026, BioLASCO Taiwan Co. Ltd. trades at a trailing price-to-earnings ratio of 18.62. The price-to-sales ratio is 2.95, and the price-to-book ratio stands at 1.79.

As of June 30, 2026, BioLASCO Taiwan Co. Ltd. trades at an EV/EBITDA multiple of 12.11 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.76 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 15.51 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. BioLASCO Taiwan Co. Ltd. trades at an EV/FCF ratio of 20.02, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 711.54M versus a market cap of 765.80M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioLASCO Taiwan Co. Ltd. maintains a current ratio of 2.32, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.36, indicating elevated leverage, while an interest coverage ratio of 27.75 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BioLASCO Taiwan Co. Ltd. posted a return on equity (ROE) of 9.56, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.44 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.76, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.16, useful for judging operating efficiency across full business cycles. The company generates approximately 2.86M in revenue per employee across its workforce of 90.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.54 indicates how many times BioLASCO Taiwan Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, BioLASCO Taiwan Co. Ltd. recorded 6.92M in income tax expense. That works out to an effective tax rate of 14.47, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 47.81M, leaving 40.89M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, BioLASCO Taiwan Co. Ltd.'s stock has declined approximately 10.24% over the past 52 weeks. The 50-day moving average sits at 29.00, while the 200-day moving average is 29.73.

Over the twelve months ended June 30, 2026, BioLASCO Taiwan Co. Ltd. generated 258.04M in revenue and converted that into 40.89M in net income, yielding earnings per share of 1.60. EBITDA reached 58.75M, while operating income came in at 45.88M.

As of June 30, 2026, BioLASCO Taiwan Co. Ltd. holds 141.27M in cash and equivalents against 87.01M in total debt, resulting in a net debt position of -77,000.00. Total book value stands at 427.45M, with working capital of 125.73M providing operational flexibility.

BioLASCO Taiwan Co. Ltd. produced 43.89M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10.15M in capital expenditures, free cash flow totaled 33.73M - equivalent to 1.32 per share.

Over the twelve months ended June 30, 2026, BioLASCO Taiwan Co. Ltd. posted a gross margin of 39.41, reflecting its pricing power and cost economics. The operating margin of 17.78 and net profit margin of 15.85 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, BioLASCO Taiwan Co. Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.43, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 7.29, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BioLASCO Taiwan Co. Ltd. shareholders.

BioLASCO Taiwan Co. Ltd.'s most recent stock split took place on July 30, 2018 with a 200:211 split ratio.

As of June 30, 2026, BioLASCO Taiwan Co. Ltd. has an Altman Z-Score of 3.68, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.